BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 34613552)

  • 21. One-Step Next-Generation Sequencing of Immunoglobulin and T-Cell Receptor Gene Recombinations for MRD Marker Identification in Acute Lymphoblastic Leukemia.
    Villarese P; Abdo C; Bertrand M; Thonier F; Giraud M; Salson M; Macintyre E
    Methods Mol Biol; 2022; 2453():43-59. PubMed ID: 35622319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing.
    Zhang H; Wang H; Qian X; Gao S; Xia J; Liu J; Cheng Y; Man J; Zhai X
    BMC Cancer; 2020 Mar; 20(1):211. PubMed ID: 32164600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
    Yang F; Anekpuritanang T; Press RD
    Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?
    Short NJ; Kantarjian H; Jabbour E
    Expert Rev Hematol; 2024 Jun; 17(6):189-191. PubMed ID: 38726703
    [No Abstract]   [Full Text] [Related]  

  • 25. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities.
    Tran TH; Hunger SP
    Semin Cancer Biol; 2022 Sep; 84():144-152. PubMed ID: 33197607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.
    Soverini S; De Benedittis C; Papayannidis C; Polakova KM; Venturi C; Russo D; Bresciani P; Iurlo A; Mancini M; Vitale A; Chiaretti S; Foà R; Abruzzese E; Sorà F; Kohlmann A; Haferlach T; Baccarani M; Cavo M; Martinelli G
    Leukemia; 2016 Jul; 30(7):1615-9. PubMed ID: 26867670
    [No Abstract]   [Full Text] [Related]  

  • 27. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of next-generation sequencing in acute myeloid leukemia.
    Llop M; Sargas C; Barragán E
    Curr Opin Oncol; 2022 Nov; 34(6):723-728. PubMed ID: 36102349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia.
    Feng J; Li Y; Jia Y; Fang Q; Gong X; Dong X; Ru K; Li Q; Zhao X; Liu K; Wang M; Tian Z; Jia Y; Wang Y; Lin D; Wei H; Tang K; Mi Y; Wang J
    J Hematol Oncol; 2017 Feb; 10(1):61. PubMed ID: 28245838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-throughput sequencing of immunoglobulin heavy chain for minimal residual disease detection in B-lymphoblastic leukemia.
    Correia RP; Puga RD; Muto NH; Lee MLM; Torres DC; Hassan R; Bacal NS; Hamerschlak N; Campregher PV
    Int J Lab Hematol; 2021 Aug; 43(4):724-731. PubMed ID: 33393719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones.
    Salson M; Giraud M; Caillault A; Grardel N; Duployez N; Ferret Y; Duez M; Herbert R; Rocher T; Sebda S; Quief S; Villenet C; Figeac M; Preudhomme C
    Leuk Res; 2017 Feb; 53():1-7. PubMed ID: 27930944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL.
    Cheng S; Inghirami G; Cheng S; Tam W
    J Hematol Oncol; 2018 Aug; 11(1):105. PubMed ID: 30134947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia.
    Heikamp EB; Pui CH
    J Pediatr; 2018 Dec; 203():14-24.e2. PubMed ID: 30213460
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical benefit of a high-throughput sequencing approach for minimal residual disease in acute lymphoblastic leukemia.
    Wright G; Watt E; Inglott S; Brooks T; Bartram J; Adams SP
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27787. PubMed ID: 31034760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph.
    Wolf J; Fonseca R; Muffly L
    Clin Adv Hematol Oncol; 2020 Mar; 18 Suppl 9(3):1-16. PubMed ID: 33843875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of minimal residual disease monitoring in pediatric patients with acute lymphoblastic leukemia.
    Qin X; Zhang MY; Liu WJ
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6885-6895. PubMed ID: 30402854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.
    Soverini S; Albano F; Bassan R; Fabbiano F; Ferrara F; Foà R; Olivieri A; Rambaldi A; Rossi G; Sica S; Specchia G; Venditti A; Barosi G; Pane F
    Cancer Med; 2020 May; 9(9):2960-2970. PubMed ID: 32154668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia.
    Fries C; Burack WR
    Leuk Res; 2018 Dec; 75():15-22. PubMed ID: 30445235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.
    DiNardo CD; Routbort MJ; Bannon SA; Benton CB; Takahashi K; Kornblau SM; Luthra R; Kanagal-Shamanna R; Medeiros LJ; Garcia-Manero G; M Kantarjian H; Futreal PA; Meric-Bernstam F; Patel KP
    Cancer; 2018 Jul; 124(13):2704-2713. PubMed ID: 29682723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical application of minimal residual disease detection in childhood acute leukemia].
    Cheng YQ; Zhai XW
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 May; 20(5):416-420. PubMed ID: 29764581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.